Evolus, Inc. (EOLS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Evolus reported revenue of $297.2M, up 11.6% from $266.3M the year before. Net income was -$51.6M (a -17.4% net margin), or -$0.80 per diluted share. Gross margin was 66.3% and operating margin was -11.0%. Operating activities generated -$42.3M of cash, leaving -$45.7M of free cash flow. At fiscal year end, Evolus held $225.9M in total assets against $249.0M in total liabilities, including $53.8M of cash and equivalents.
Open the full interactive Evolus financials → Quarterly statements, key ratios, valuation history and price charts.
Evolus Key Stats
| Share Price | $7.51 |
|---|---|
| Market Cap | $495.1M |
| Revenue YoY Growth | +11.6% |
| 52-Week Range | $3.94 – $9.30 |
| Shares Outstanding | 65.9 million (basic, 2026 Q2) |
Evolus Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $56.5M | $99.7M | $148.6M | $202.1M | $266.3M | $297.2M |
| Cost of Goods Sold | $18.3M | $43.5M | $55.9M | $61.6M | $84.0M | $100.1M |
| Gross Profit | $38.2M | $56.1M | $92.7M | $140.5M | $182.3M | $197.1M |
| Operating Income | -$153.1M | -$44.4M | -$65.3M | -$49.2M | -$34.4M | -$32.7M |
| Pre-Tax Income | -$162.9M | -$46.8M | -$74.3M | -$61.5M | -$49.8M | -$51.0M |
| Income Tax | $77,000 | $42,000 | $95,000 | $176,000 | $664,000 | $677,000 |
| Net Income | -$163.0M | -$46.8M | -$74.4M | -$61.7M | -$50.4M | -$51.6M |
| Diluted EPS | -$4.83 | -$0.94 | -$1.33 | -$1.08 | -$0.81 | -$0.80 |
Evolus Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $69.0M | $90.3M | $73.1M | $84.1M |
| Net Income | -$15.7M | $130,000 | -$10.7M | -$8.1M |
| Diluted EPS | -$0.24 | $0.00 | -$0.16 | -$0.12 |
Evolus Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $102.6M | $146.3M | $53.9M | $62.8M | $87.0M | $53.8M |
| Current Assets | $127.6M | $178.8M | $100.8M | $112.4M | $151.3M | $142.9M |
| Total Assets | $209.1M | $257.5M | $178.0M | $189.0M | $232.6M | $225.9M |
| Current Liabilities | $180.2M | $57.7M | $46.5M | $48.3M | $63.0M | $75.3M |
| Total Long-Term Debt | $40.5M | $71.2M | $71.9M | $120.4M | $121.5M | $146.1M |
| Total Liabilities | $282.0M | $175.6M | $159.5M | $209.7M | $227.0M | $249.0M |
| Shareholders' Equity | -$73.0M | $81.9M | $18.5M | -$20.7M | $5.5M | -$23.1M |
Evolus Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$57.9M | -$33.4M | -$84.9M | -$34.0M | -$18.0M | -$42.3M |
| Cash From Investing | $12.2M | $4.0M | -$2.9M | -$1.6M | -$4.8M | -$8.5M |
| Cash From Financing | $38.3M | $73.1M | -$4.1M | $44.6M | $47.4M | $17.3M |
| Free Cash Flow | -$58.7M | -$33.8M | -$86.5M | -$34.5M | -$19.5M | -$45.7M |
Figures from Evolus' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Evolus financials page for every line item.
Evolus Company Profile
| Ticker | EOLS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Newport Beach, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001570562 |
Frequently Asked Questions
What was Evolus' revenue in fiscal 2025?
Evolus (EOLS) reported revenue of $297.2M for fiscal 2025.
What is Evolus' annual revenue history?
Evolus' annual revenue by fiscal year: 2020: $56.5M; 2021: $99.7M; 2022: $148.6M; 2023: $202.1M; 2024: $266.3M; 2025: $297.2M.
What was Evolus' net income in fiscal 2025?
Evolus reported net income of -$51.6M for fiscal 2025.
What was Evolus' earnings per share (EPS) in fiscal 2025?
Evolus' diluted EPS was -$0.80 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Evolus generate in fiscal 2025?
Evolus generated -$45.7M of free cash flow in fiscal 2025.
What was Evolus' revenue last quarter?
In its most recent reported quarter (2026 Q2), Evolus reported revenue of $84.1M.
How much debt does Evolus have?
Evolus reported $146.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Evolus are outstanding?
Evolus reported a weighted average of 65.9 million basic shares outstanding in 2026 Q2.
What is Evolus' market cap?
Based on its latest closing price, Evolus (EOLS) has a market capitalization of about $495.1M.
When does Evolus' fiscal year end?
Evolus' fiscal year end, as registered with the SEC, is December 31.
Where is Evolus headquartered?
Evolus lists its business address in Newport Beach, California in its SEC filings.